Prepared From Virus, Prokaryotic Acid Patents (Class 435/91.32)
  • Patent number: 6613516
    Abstract: The presently claimed invention provides methods, compositions, and apparatus for studying nucleic acids. Specifically, the present invention provides a novel enrichment and labeling strategy for ribonucleic acids. In one embodiment, the invention provides enriching for a population of interest in a complex population by diminishing the presence of a target sequence. In a further embodiment, the invention can be used to reproducibly label and detect extremely small amounts of nucleic acids.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: September 2, 2003
    Assignee: Affymetrix, Inc.
    Inventors: Fred C. Christians, Duc Do, Thomas Gingeras, Kevin Gunderson, Charles G. Miyada, Carsten Rosenow, Kai Wu, Qing Yang
  • Patent number: 6596268
    Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering a immunosuppressive agent.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: July 22, 2003
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Bradley G. Thompson
  • Patent number: 6573092
    Abstract: The inventive method of producing a eukaryotic viral vector comprises contacting a eukaryotic cell, which comprises a unique enzyme that nicks or cleaves a DNA molecule, with a recombinant phage vector, or contacting a eukaryotic cell, which does not comprise a unique enzyme that nicks or cleaves a DNA molecule, simultaneously or sequentially, in either order, with (i) a unique enzyme that nicks or cleaves a DNA molecule, and (ii) a recombinant phage vector. The recombinant phage vector comprises the DNA molecule comprising (a) a eukaryotic viral vector genome comprising a coding sequence, (b) a phage packaging site that is not contained within the eukaryotic viral vector genome, and (c) a promoter that is operably linked to the coding sequence.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: June 3, 2003
    Assignee: GenVec, Inc.
    Inventors: Imre Kovesdi, Duncan L. McVey
  • Patent number: 6514694
    Abstract: The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are compositions comprising such proteins, nucleic acid molecules and/or antibodies, as well as the use of such compositions to inhibit oocyst shedding by cats due to infection with T. gondii. The present invention also includes the use of certain T. gondii-based antisera to identify such nucleic acid molecules and proteins, as well as nucleic acid molecules and proteins identified by such methods. The present invention also relates to novel methods for the detection of cysts and oocysts.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: February 4, 2003
    Assignee: Heska Corporation
    Inventor: Michael James Milhausen
  • Publication number: 20020182228
    Abstract: Isolated polynucleotide molecules provide RSV genome and antigenomes, including that of human, bovine or murine RSV or RSV-like viruses, and chimera thereof. The recombinant genome or antigenome can be expressed with a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large (L) polymerase protein, and an RNA polymerase elongation factor to produce isolated infectious RSV particles. The recombinant RSV genome and antigenome can be modified to produce desired phenotypic changes, such as attenuated viruses for vaccine use.
    Type: Application
    Filed: May 3, 2001
    Publication date: December 5, 2002
    Inventor: Peter L. Collins
  • Patent number: 6392124
    Abstract: The infectious clone comprises: a) a complete copy of the complementary DNA (cDNA) to the genomic RNA of the turnip mosaic virus (TuMV), in the form of double stranded DNA, b) a transcription promoter sequence, c) a replicon and, optionally, d) a transcription termination or polyadenilation sequence. Viral vectors comprise an infectious clone modified to contain a gene or a heterologous gene fragment. Infectious viral clones and vectors are useful for basic research, in virology and for the expression of genes and epitopes of interest.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: May 21, 2002
    Assignee: Institute Nacional de Investigacion Y Tecnologia Agraria Y Alimentaria (INIA)
    Inventors: Fernando Ponz Ascaso, Vicente Torres Pascual, Florentina Sanchez Sanchez, David Martinez Herrera
  • Publication number: 20020034734
    Abstract: The invention concerns a pharmaceutical composition for treating or preventing C hepatitis (HCV), induced infections, which in a preferred embodiment, comprises a main active principle, (i) a fusion polypeptide, including the HCV capsid polypeptide (C191) and polypeptide coat (E1) and in which at least one cleavage site 173/174 and 191/192 has been made inoperative by mutation; (ii) an equimolar mixture of the C191 polypeptide of which the cleavage site 173/174 has been made inoperative and of the E1 polypeptide (mixture equivalent to the fusion polypeptide); or (iii) a DNA molecule coding for this fusion polypeptide. Products (i) to (iii) are characterized in that the C191 element is incapable of regulating the functioning of the genes, in particular of causing them to interact. Such a composition can also include any form equivalent to the products described above.
    Type: Application
    Filed: July 26, 2001
    Publication date: March 21, 2002
    Applicant: Pasteur Merieux Serums & Vaccins
    Inventor: Veronique Barban
  • Patent number: 6331417
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising: (i) a primer protion consisting of a contiguous sequence of from 10 to 50 nucleotides capable of hybridizing to (a) the target nucleic acid molecule represented by SEQ ID NO:1, or (b) to the complementary stand thereof; and optional (ii) a further portion comprising from 1 to 25 nucleotides joined to and immediately 5′ to the 5′ end of the primer portion.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: December 18, 2001
    Assignee: Royal Free Hospital School of Medicine
    Inventors: Vincent C Emery, Paul Griffiths
  • Patent number: 6284249
    Abstract: The invention concerns a pharmaceutical composition for treating or preventing C hepatitis (HCV), induced infections, which in a preferred embodiment, comprises a main active principle, (i) a fusion polypeptide, including the HCV capsid polypeptide (C191) and polypeptide coat (E1) and in which at least one cleavage site 173/174 and 191/192 has been made inoperative by mutation; (ii) an equimolar mixture of the C191 polypeptide of which the cleavage site 173/174 has been made inoperative and of the E1 polypeptide (mixture equivalent to the fusion polypeptide); or (iii) a DNA molecule coding for this fusion polypeptide. Products (i) to (iii) are characterized in that the C191 element is incapable of regulating the functioning of the genes, in particular of causing them to interact. Such a composition can also include any form equivalent to the products described above.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: September 4, 2001
    Assignee: Pasteur Merieux Sérums & Vaccins
    Inventor: Véronique Barban
  • Patent number: 6280974
    Abstract: The present invention provides polynucleotide molecules encoding portions of the S protein from feline infectious peritonitis virus (FIPV). The present invention further provides polynucleotide molecules encoding the entire S protein or portions thereof from feline enteric coronavirus (FECV). The polynucleotide molecules of the present invention are useful as diagnostic reagents.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: August 28, 2001
    Assignee: Pfizer Inc
    Inventors: Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones
  • Publication number: 20010014447
    Abstract: The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are compositions comprising such proteins, nucleic acid molecules and/or antibodies, as well as the use of such compositions to inhibit oocyst shedding by cats due to infection with T. gondii. The present invention also includes the use of certain T. gondii-based antisera to identify such nucleic acid molecules and proteins, as well as nucleic acid molecules and proteins identified by such methods. The present invention also relates to novel methods for the detection of cysts and oocysts.
    Type: Application
    Filed: December 18, 1998
    Publication date: August 16, 2001
    Inventor: MICHAEL J. MILHAUSEN
  • Patent number: 6245528
    Abstract: The invention relates to a baculovirus including a disruption in its endogenous p35 gene and its use in establishing latent baculovirus infections. In some embodiments, the baculovirus can also include a sequence encoding a non-baculovirus RNA and a baculovirus early gene promoter which drives expression of the non-baculovirus RNA.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: June 12, 2001
    Assignee: Academia Sinica
    Inventor: Yu-Chan Chao
  • Patent number: 6218105
    Abstract: A high throughput virus in vitro infectivity assay method comprising growing cells in a multi-well format, infecting the cells with intact virion incubated with a test agent, and measuring expression of at least one viral nucleic acid sequence in the cells. The method also preferably comprises incubating intact virion without test agent to define a control. The cells are preferably human keratinocyte cells grown in monolayers. The viral nucleic acid sequence will generally comprise viral mRNA. In one preferred embodiment, the intact virion comprise Human Papilloma Virus, and more preferably Human Papilloma Virus-11. Measuring expression is generally carried out by releasing the viral mRNA from the cells by lysis, amplifying the mRNA as CDNA via RT-PCR, and detecting amplicons with specific probes. Cell lysis may be carried out by heating or by treatment with detergent.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: April 17, 2001
    Inventors: Kathleen S. Hall, Lloyd H. Smith
  • Patent number: 6197944
    Abstract: The use of oligodeoxynucleotides modified at the 3′-terminal internucleotide link as therapeutic agents by a method of hybridizing the modified oligonucleotide to a complementary sequence within a targeted mRNA and cleaving the mRNA within the RNA-DNA helix by the enzyme RNaseH to block the expression of the corresponding gene.
    Type: Grant
    Filed: June 29, 1994
    Date of Patent: March 6, 2001
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Joseph A. Walder, Roxanne Y. Walder, Paul S. Eder, John M. Dagle